Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing

Jessica Mendoza

👤 Person
4059 total appearances

Appearances Over Time

Podcast Appearances

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tell me about the company behind this blockbuster drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tell me about the company behind this blockbuster drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tell me about the company behind this blockbuster drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tremendous growth, strong sales, rising profits. Novo is a success story, which makes the latest news from the company all the more surprising.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tremendous growth, strong sales, rising profits. Novo is a success story, which makes the latest news from the company all the more surprising.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tremendous growth, strong sales, rising profits. Novo is a success story, which makes the latest news from the company all the more surprising.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

By leaving, do we mean he's resigning? Is he retiring? What's going on?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

By leaving, do we mean he's resigning? Is he retiring? What's going on?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

By leaving, do we mean he's resigning? Is he retiring? What's going on?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Welcome to The Journal, our show about money, business, and power. I'm Jessica Mendoza. It's Wednesday, May 21st. Coming up on the show, Ozempic is a huge hit. So why is the drugmaker's CEO out? For most of its hundred-year history, Novo Nordisk was known mainly as a maker of insulin.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Welcome to The Journal, our show about money, business, and power. I'm Jessica Mendoza. It's Wednesday, May 21st. Coming up on the show, Ozempic is a huge hit. So why is the drugmaker's CEO out? For most of its hundred-year history, Novo Nordisk was known mainly as a maker of insulin.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Welcome to The Journal, our show about money, business, and power. I'm Jessica Mendoza. It's Wednesday, May 21st. Coming up on the show, Ozempic is a huge hit. So why is the drugmaker's CEO out? For most of its hundred-year history, Novo Nordisk was known mainly as a maker of insulin.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Novo's corporate headquarters outside of Copenhagen is even designed to mimic the winding structure of an insulin molecule. The company is also uniquely Danish in its corporate structure.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Novo's corporate headquarters outside of Copenhagen is even designed to mimic the winding structure of an insulin molecule. The company is also uniquely Danish in its corporate structure.